PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors

Journal of Neuroscience

Volumn 29, Issue 22, 2009, Pages 7124-7136

  Abbas, Atheir I ^a   Yadav, Prem N ^b   Yao, Wei Dong ^d,e   Arbuckle, Margaret I ^f   Grant, Seth G N ^f,g   Caron, Marc G ^d   Roth, Bryan L ^a,b,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

^g WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; G PROTEIN COUPLED RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; IONOTROPIC RECEPTOR; POSTSYNAPTIC DENSITY PROTEIN 95; PSYCHEDELIC AGENT; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DENDRITE; DRUG MECHANISM; GENE DELETION; IN VIVO STUDY; MOUSE; MUSCLE TWITCH; NONHUMAN; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; ANTIPSYCHOTIC AGENTS; CEREBRAL CORTEX; GENE EXPRESSION REGULATION; GREEN FLUORESCENT PROTEINS; HALLUCINOGENS; HYPOTHERMIA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MICROTUBULE-ASSOCIATED PROTEINS; NEURAL INHIBITION; NEURONS; PROTEIN BINDING; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-FOS; PYRAZINES; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN; RNA, MESSENGER; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; TRANSDUCTION, GENETIC;

EID: 66749118877     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1090-09.2009     Document Type: Article

References (81)

1. Aghajanian GK, Marek GJ (1999) Serotonin and hallucinogens. Neuropsychopharmacology 21:16S-23S. (Pubitemid 29396466)
2. Ahlemeyer B, Baumgart-Vogt E (2005) Optimized protocols for the simultaneous preparation of primary neuronal cultures of the neocortex, hippocampus and cerebellum from individual newborn (P0.5) C57BL/6J mice. J Neurosci Methods 149:110-120. (Pubitemid 41642578)
3. Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, Ghisi V, Wetsel WC, Lefkowitz RJ, Gainetdinov RR, Caron MG (2008) A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 132:125-136.
4. Bécamel C, Alonso G, Galéotti N, Demey E, Jouin P, Ullmer C, Dumuis A, Bockaert J, Marin P (2002) Synaptic multiprotein complexes associated with 5-HT(2C) receptors: a proteomic approach. EMBO J 21:2332-2342. (Pubitemid 34546706)
5. Bécamel C, Gavarini S, Chanrion B, Alonso G, Galéotti N, Dumuis A, Bockaert J, Marin P (2004) The serotonin 5-HT2A and 5-HT2C receptors interact with specific sets of PDZ proteins. J Biol Chem 279:20257-20266. (Pubitemid 38623471)
6. Berg KA, Cropper JD, Niswender CM, Sanders-Bush E, Emeson RB, Clarke WP (2001) RNA-editing of the 5-HT(2C) receptor alters agonist-receptor-effector coupling specificity. Br J Pharmacol 134:386-392. (Pubitemid 32989136)
7. Berger M, Gray JA, Roth BL (2009) The expanded biology of serotonin receptors. Annu Rev Med 60:355-366.
8. Burns CM, Chu H, Rueter SM, Hutchinson LK, Canton H, Sanders-Bush E, Emeson RB (1997) Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature 387:303-308. (Pubitemid 27220768)
9. Caceres A, Banker G, Steward O, Binder L, Payne M (1984) MAP2 is localized to the dendrites of hippocampal neurons which develop in culture. Brain Res 315:314-318. (Pubitemid 14107877)
10. Campbell BM, Merchant KM (2003) Serotonin 2C receptors within the basolateral amygdala induce acute fear-like responses in an open-field environment. Brain Res 993:1-9. (Pubitemid 37464577)
11. Carlsson ML, Martin P, Nilsson M, Sorensen SM, Carlsson A, Waters S, Waters N (1999) The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist-than dopamine agonist-induced hyperactivity in mice. J Neural Transm 106:123-129. (Pubitemid 29137509)
12. Chaudhuri A (1997) Neural activity mapping with inducible transcription factors. Neuroreport 8:v-ix.
13. Chen L, Chetkovich DM, Petralia RS, Sweeney NT, Kawasaki Y, Wenthold RJ, Bredt DS, Nicoll RA (2000) Stargazin regulates synaptic targeting of AMPA receptors by two distinct mechanisms. Nature 408:936-943. (Pubitemid 32101633)
14. Clemett DA, Punhani T, Duxon MS, Blackburn TP, Fone KC (2000) Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS. Neuropharmacology 39:123-132.
15. Du Y, Davisson MT, Kafadar K, Gardiner K (2006) A-to-I pre-mRNA editing of the serotonin 2C receptor: comparisons among inbred mouse strains. Gene 382:39-46. (Pubitemid 44548253)
16. Dunlop J, Sabb AL, Mazandarani H, Zhang J, Kalgaonker S, Shukhina E, Sukoff S, Vogel RL, Stack G, Schechter L, Harrison BL, Rosenzweig-Lipson S (2005) WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10aoctahydro-7bH-cyclopenta-[b][1, 4]diazepino[6,7,1h i]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity. J Pharmacol Exp Ther 313:862-869.
17. Dunlop J, Marquis KL, Lim HK, Leung L, Kao J, Cheesman C, Rosenzweig-Lipson S (2006) Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909; therapeutic potential in multiple indications. CNS Drug Rev 12:167-177. (Pubitemid 46047786)
18. Ehrlich I, Malinow R (2004) Postsynaptic density 95 controls AMPA receptor incorporation during long-term potentiation and experience-driven synaptic plasticity. J Neurosci 24:916-927. (Pubitemid 38146602)
19. Gavarini S, Bécamel C, Altier C, Lory P, Poncet J, Wijnholds J, Bockaert J, Marin P (2006) Opposite effects of PSD-95 and MPP3 PDZ proteins on serotonin 5-hydroxytryptamine2C receptor desensitization and membrane stability. Mol Biol Cell 17:4619-4631. (Pubitemid 44665733)
20. Geyer MA, Ellenbroek B (2003) Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27:1071-1079. (Pubitemid 37464953)
21. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156:117-154. (Pubitemid 32702206)
22. Gleason SD, Shannon HE (1997) Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology (Berl) 129:79-84. (Pubitemid 27037454)
23. Glennon RA, Young R, Rosecrans JA (1983) Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists. Eur J Pharmacol 91:189-196.
24. Glennon RA, Titeler M, McKenney JD (1984) Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35:2505-2511. (Pubitemid 15212191)
25. González-Maeso J, Yuen T, Ebersole BJ, Wurmbach E, Lira A, Zhou M, Weisstaub N, Hen R, Gingrich JA, Sealfon SC (2003) Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci 23:8836-8843. (Pubitemid 37210895)
26. González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA (2007) Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53:439-452. (Pubitemid 46161267)
27. 2A receptor induces ERK phosphorylation and proliferation through ADAM-17 tumor necrosis factor-alpha-converting enzyme (TACE) activation and heparin-bound epidermal growth factor-like growth factor (HB-EGF) shedding in mesangial cells. J Biol Chem 281:21004-21012.
28. Gray JA, Roth BL (2007) The pipeline and future of drug development in schizophrenia. Mol Psychiatry 12:904-922. (Pubitemid 47482704)
29. Greene EL, Houghton O, Collinsworth G, Garnovskaya MN, Nagai T, Sajjad T, Bheemanathini V, Grewal JS, Paul RV, Raymond JR (2000) 5-HT(2A) receptors stimulate mitogen-activated protein kinase via H(2)O(2) generation in rat renal mesangial cells. Am J Physiol Renal Physiol 278:F650-F658.
30. Hershenson MB, Chao TS, Abe MK, Gomes I, Kelleher MD, Solway J, Rosner MR (1995) Histamine antagonizes serotonin and growth factor-induced mitogen-activated protein kinase activation in bovine tracheal smooth muscle cells. J Biol Chem 270:19908-19913.
31. Imamura F, Maeda S, Doi T, Fujiyoshi Y (2002) Ligand binding of the second PDZ domain regulates clustering of PSD-95 with the Kv1.4 potassium channel. J Biol Chem 277:3640-3646. (Pubitemid 34953237)
32. Jakab RL, Goldman-Rakic PS (1998) 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci U S A 95:735-740. (Pubitemid 28083813)
33. Javitt DC (2004) Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 9:984-997, 979.
34. Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-225. (Pubitemid 29067401)
35. Johnson-Farley NN, Kertesy SB, Dubyak GR, Cowen DS (2005) Enhanced activation of Akt and extracellular-regulated kinase pathways by simultaneous occupancy of Gq-coupled 5-HT2A receptors and Gs-coupled 5-HT7A receptors in PC12 cells. J Neurochem 92:72-82. (Pubitemid 40193510)
36. Kim S, Burette A, Chung HS, Kwon SK, Woo J, Lee HW, Kim K, Kim H, Weinberg RJ, Kim E (2006) NGL family PSD-95-interacting adhesion molecules regulate excitatory synapse formation. Nat Neurosci 9:1294-1301. (Pubitemid 44454271)
37. LaBerge D (2006) Apical dendrite activity in cognition and consciousness. Conscious Cogn 15:235-257. (Pubitemid 43729547)
38. Laberge D, Kasevich R (2007) The apical dendrite theory of consciousness. Neural Netw 20:1004-1020. (Pubitemid 350061129)
39. Li X, Zhu W, Roh MS, Friedman AB, Rosborough K, Jope RS (2004) In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology 29:1426-1431.
40. Linn GS, Javitt DC (2001) Phencyclidine (PCP)-induced deficits of prepulse inhibition in monkeys. Neuroreport 12:117-120. (Pubitemid 32099039)
41. Linn GS, Negi SS, Gerum SV, Javitt DC (2003) Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys. Psychopharmacology (Berl) 169:234-239. (Pubitemid 37255515)
42. Lo RK, Wong YH (2006) Transcriptional activation of c-Fos by constitutively active Galpha(16)QL through a STAT1-dependent pathway. Cell Signal 18:2143-2153.
43. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D (2002) Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 295:868-872. (Pubitemid 34118370)
44. López-Giménez JF, Tecott LH, Palacios JM, Mengod G, Vilaró T (2002) Serotonin 5-HT (2C) receptor knockout mice: autoradiographic analysis of multiple serotonin receptors. J Neurosci Res 67:69-85. (Pubitemid 34052054)
45. Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA, Grauer SM, Ashby CR Jr, Nguyen HQ, Dawson LA, Barrett JE, Stack G, Meltzer HY, Harrison BL, Rosenzweig-Lipson S (2007) WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a- octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: a novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. J Pharmacol Exp Ther 320:486-496.
46. Martin KF, Phillips I, Hearson M, Prow MR, Heal DJ (1992) Characterization of 8-OH-DPAT-induced hypothermia in mice as a 5-HT1A autoreceptor response and its evaluation as a model to selectively identify antidepressants. Br J Pharmacol 107:15-21.
47. Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238-246. (Pubitemid 19261970)
48. Meltzer HY, Arvanitis L, Bauer D, Rein W (2004) Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 161:975-984. (Pubitemid 38735983)
49. Migaud M, Charlesworth P, Dempster M, Webster LC, Watabe AM, Makhinson M, He Y, Ramsay MF, Morris RG, Morrison JH, O'Dell TJ, Grant SG (1998) Enhanced long-term potentiation and impaired learning in mice with mutant postsynaptic density-95 protein. Nature 396:433-439. (Pubitemid 28553306)
50. Molineaux SM, Jessell TM, Axel R, Julius D (1989) 5-HT1c receptor is a prominent serotonin receptor subtype in the central nervous system. Proc Natl Acad Sci U S A 86:6793-6797.
51. Nichols CD, Sanders-Bush E (2002) A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain. Neuropsychopharmacology 26:634-642. (Pubitemid 34260982)
52. Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131-181.
53. Nicoll RA, Tomita S, Bredt DS (2006) Auxiliary subunits assist AMPA-type glutamate receptors. Science 311:1253-1256. (Pubitemid 43334707)
54. Niswender CM, Copeland SC, Herrick-Davis K, Emeson RB, Sanders-Bush E (1999) RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J Biol Chem 274:9472-9478. (Pubitemid 129517919)
55. Olney JW, Newcomer JW, Farber NB (1999) NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33:523-533.
56. Pereira MG, Gitaí DL, Paçó-Larson ML, Pesquero JB, Garcia-Cairasco N, Costa-Neto CM (2008) Modulation of B1 and B2 kinin receptors expression levels in the hippocampus of rats after audiogenic kindling and with limbic recruitment, a model of temporal lobe epilepsy. Int Immunopharmacol 8:200-205.
57. Pinto W, Battaglia G (1994) Comparative recovery kinetics of 5-hydroxytryptamine 1A, 1B, and 2A receptor subtypes in rat cortex after receptor inactivation: evidence for differences in receptor production and degradation. Mol Pharmacol 46:1111-1119.
58. Price RD, Sanders-Bush E (2000) RNA editing of the human serotonin 5-HT(2C) receptor delays agonist-stimulated calcium release. Mol Pharmacol 58:859-862.
59. Quinn JC, Johnson-Farley NN, Yoon J, Cowen DS (2002) Activation of extracellular-regulated kinase by 5-hydroxytryptamine(2A) receptors in PC12 cells is protein kinase C-independent and requires calmodulin and tyrosine kinases. J Pharmacol Exp Ther 303:746-752. (Pubitemid 35231251)
60. Rauser L, Savage JE, Meltzer HY, Roth BL (2001) Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J Pharmacol Exp Ther 299:83-89. (Pubitemid 32905121)
61. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB (2002) Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A 99:11934-11939. (Pubitemid 34994502)
62. Roth BL, Sheffler DJ, Kroeze WK (2004a) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3:353-359. (Pubitemid 38499762)
63. Roth BL, Lopez E, Beischel S, Westkaemper RB, Evans JM (2004b) Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery. Pharmacol Ther 102:99-110. (Pubitemid 38681010)
64. Sard H, Kumaran G, Morency C, Roth BL, Toth BA, He P, Shuster L (2005) SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett 15:4555-4559. (Pubitemid 41253894)
65. Schlüter OM, Xu W, Malenka RC (2006) Alternative N-terminal domains of PSD-95 and SAP97 govern activity-dependent regulation of synaptic AMPA receptor function. Neuron 51:99-111. (Pubitemid 43963332)
66. Schmid CL, Raehal KM, Bohn LM (2008) Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc Natl Acad Sci U S A 105:1079-1084.
67. Sheng M, Kim MJ (2002) Postsynaptic signaling and plasticity mechanisms. Science 298:776-780. (Pubitemid 35231521)
68. Spratling MW (2002) Cortical region interactions and the functional role of apical dendrites. Behav Cogn Neurosci Rev 1:219-228.
69. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, Julius D (1995) Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 374:542-546.
70. Tecott LH, Logue SF, Wehner JM, Kauer JA (1998) Perturbed dentate gyrus function in serotonin 5-HT2C receptor mutant mice. Proc Natl Acad Sci U S A 95:15026-15031. (Pubitemid 29003750)
71. Thomsen WJ, Grottick AJ, Menzaghi F, Reyes-Saldana H, Espitia S, Yuskin D, Whelan K, Martin M, Morgan M, Chen W, Al-Shamma H, Smith B, Chalmers D, Behan D (2008) Lorcaserin, a novel selective human 5-HT2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 325:577-587.
72. Tononi G, Edelman GM (1998) Consciousness and complexity. Science 282:1846-1851. (Pubitemid 28555257)
73. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13. (Pubitemid 46025713)
74. Varty GB, Bakshi VP, Geyer MA (1999) M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsychopharmacology 20:311-321.
75. Wieraszko A, Seyfried TN (1993) Influence of audiogenic seizures on synaptic facilitation in mouse hippocampal slices is mediated by N-methyl-D-aspartate receptor. Epilepsia 34:979-984. (Pubitemid 24004232)
76. Willins DL, Deutch AY, Roth BL (1997) Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 27:79-82. (Pubitemid 27327604)
77. Xia Z, Gray JA, Compton-Toth BA, Roth BL (2003a) A direct interaction of PSD-95 with 5-HT2A serotonin receptors regulates receptor trafficking and signal transduction. J Biol Chem 278:21901-21908. (Pubitemid 36792597)
78. Xia Z, Hufeisen SJ, Gray JA, Roth BL (2003b) The PDZ-binding domain is essential for the dendritic targeting of 5-HT2A serotonin receptors in cortical pyramidal neurons in vitro. Neuroscience 122:907-920. (Pubitemid 37485844)
79. Xu W, Schlüter OM, Steiner P, Czervionke BL, Sabatini B, Malenka RC (2008) Molecular dissociation of the role of PSD-95 in regulating synaptic strength and LTD. Neuron 57:248-262.
80. Yamada S, Harano M, Annoh N, Nakamura K, Tanaka M (1999) Involvement of serotonin 2A receptors in phencyclidine-induced disruption of prepulse inhibition of the acoustic startle in rats. Biol Psychiatry 46:832-838. (Pubitemid 29460911)
81. Yao WD, Gainetdinov RR, Arbuckle MI, Sotnikova TD, Cyr M, Beaulieu JM, Torres GE, Grant SG, Caron MG (2004) Identification of PSD-95 as a regulator of dopamine-mediated synaptic and behavioral plasticity. Neuron 41:625-638. (Pubitemid 38253073)